Search Results for “Clinical Trial” – Page 112 – media

Development of Eye Drop for AMD

Age-related Macular Degeneration (AMD) is the leading cause of blindness among the elderly. The most commonly used drugs to slow the progression of the disease is Roche’s Lucentis and Regeneron’s Eylea. These drugs are injected into the eye which, needless to say, leads to more inconvenience.
- Source: FierceBiotech
- 866
- July 23, 2018
blindness Clinical Trials
Discovery of Novel Target in Multiple Sclerosis

Multiple sclerosis is a neurological disease affecting the myelin sheath that surrounds nerve fibers in the central nervous system, composed of the brain, spinal cord, and optic nerve. Since myelin is destroyed, it creates lesions which leads to an interruption in communication between the brain cells.
- Source: Medical News Today
- 629
- July 23, 2018
multiple sclerosis Researches
New 3D Color X-Rays to Diagnose Cancer, Heart Disease and More

The first-ever 3D, color X-rays were tested on a human by New Zealand Scientists, using technology that promises to enhance medical diagnostics in oncology, cardiology, neurology and orthopedics.
- Source: Medical Design and Outsourcing
- 1,211
- July 20, 2018
3D medical device New Approvals x-ray
Investigational Therapy For ALS Extends Patient Survival

In the United States alone, there are an estimated 20,000 people living with amyotrophic lateral sclerosis (ALS), also called as Lou Gehrig's disease. The fatal disease destroys the nerve cells which control breathing, walking, and eating. Very few people survive more than three years after being diagnosed.
- Source: EurekAlert
- 529
- July 19, 2018
ALS Lou Gehrig's Disease Researches
Spero Gets Grant of $54M for Biodefense R&D for SPR994

Spero Therapeutics granted $15.7 million for research on SPR994, its oral carbapenem-class candidate, to study the drug’s efficacy against biological threats like anthrax, plague and melioidosis as a part of an interagency collaboration.
- Source: FierceBiotech
- 798
- July 18, 2018
biotech Company Insight
mHealth Wearable Effective in Detecting AFib, STSI Study Finds

iBeat, a San Francisco-based start-up, launched a new pulse sensitive feature called iBeat Heart Watch which alerts healthcare professionals if it detects someone going into cardiac arrest.
- Source: MobiHealthNews
- 775
- July 13, 2018
atrial fibrillation Company Insight mHealth
Bristol-Myers Squibb’s Combo Drug gets FDA Approval

Bristol-Myers Squibb’s recent immunotherapy combo won FDA approval for patients with a rare colon cancer. The combinational medicine was formulated between an older medicine named Yervoy and a new cancer-fighter Opdivo. This combo drug focuses on repairing the mismatch gene.
- Source: FiercePharma
- 4,403
- July 13, 2018
Bristol-Myers Squibb cancer colorectal cancer New Approvals
Precision Medicine – A Huge Challenge for Hospital Decision Makers

The healthcare sector has gained its entry into the new era of genomics and precision medicine. There are numerous health IT vendors, who offer to help healthcare providers by providing the right data with the objective of utmost patient care.
- Source: HealthcareIT
- 819
- July 12, 2018
Market Views precision medicine
Torque’s T cell ‘Backpacks’ Show Promising Results Against Solid Tumors

Gilead’s Yescarta and Novartis’ Kymriah garnered a lot of interest among T-cell therapies after producing high response rates in patients with lymphoma and leukemia. However, the same has not been true for this technology in cases of solid tumors. In this novel procedure, patients’ immune-boosting T cells are extracted and engineered to target and destroy cancer cells.
- Source: FierceBiotech
- 1,111
- July 11, 2018
cancer Researches T-cell therapies
FDA Approves Pulmonx’s Zephyr Device to Treat Emphysema

The premarket approval of Pulmonx’s Zephyr Endobronchial Valve to treat severe emphysema has green-lighted by the FDA. Zephyr is a pencil eraser-sized device delivered directly to the lung in a minimally invasive procedure. After the successful delivery, the device stops air from entering diseased parts of the lung during breathing. This mechanism prevents the air from getting trapped by damaged alveoli and stops the breathing difficulties.
- Source: FierceBiotech
- 881
- July 4, 2018
emphysema FDA medtech New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.